RE: KRAS National Post - Part II -https://www.nationalpost.com/life/story.html?id=1639945
“The translational implications of both reports are important andimmediate,” wrote Charles L. Sawyers,
an HHMI investigator at MemorialSloan-Kettering Cancer Center. Sawyers discussed the implications ofthe research in a preview article published in the same issue of
Cell.
“The new mantra, quite simply, is that cancers bearing oncogenicmutations in a kinase are dependent on that kinase for growth andsurvival,” writes Sawyers in Cell. “With rare exception, patients withsuch tumors have derived significant benefit (that is, their tumorsshrink) when treated with an inhibitor of that mutant kinase.
Theprobability of success in such patients is so high that drug discoveryprograms can (and should) be launched when a new kinase mutation isdiscovered in a subset of human cancers
Proof:
https://www.mskcc.org/mskcc/html/2270.cfm?IRBNO=08-160
Sloan-Kettering Cancer Center...
This is the same Center and only US center testing 4601 for GBM.
Oncology world is a small world...
Researchers are aware of 4601...
I've been screaming out of my lungs as to how there is little risk as to 4601 being successful. Don't believe me, believe the experts themselves...
Yeah, I am pretty much sure that someone will takeover TLN. So sure that I am betting against the market!
By the way, 4601 is not just effective for KRAS mutation but a host of other mutations
https://www.thallion.com/docs/publications/26.AACR09-Batist-Web.pdf
T790M and EGFr L858R mutation as per poster.
But also other undisclosed, unreleased mutations....